Applicability conclusion
NovaPharm is a UK commercial organisation preparing to supply goods and services, but no verified evidence currently shows consolidated global turnover of at least GBP 36 million. On the information available, the mandatory section 54 publication duty has not been established. The Board will reassess turnover, group relationships and UK business activity annually and after a material transaction. If the duty applies, NovaPharm will prepare a financial-year-specific statement for board approval and director signature.
Commitment
NovaPharm opposes forced labour, servitude, human trafficking and exploitative recruitment. The company expects lawful work, freely chosen employment, safe conditions, fair treatment and transparent subcontracting in its own operations and supply relationships.
Pharmaceutical supply-chain risks
Risk assessment will consider manufacturing and raw-material labour; packaging; overseas sourcing; warehousing and temperature-controlled logistics; transport subcontractors; cleaning and facilities; recruitment and temporary labour; and CMO, CDMO, wholesaler and other subcontractor chains. Country, labour model, worker vulnerability, use of agents and visibility beyond the first tier may affect risk.
Due diligence and response
Planned onboarding will collect ownership, licence, site, labour-practice and subcontracting information proportionate to risk; include contractual expectations and escalation routes; and record review decisions in the supplier master and controlled documents. Higher-risk evidence may require clarification, independent information or a corrective plan before approval. NovaPharm will not claim that audits, training or remediation occurred until records verify them. A concern will be assessed with worker safety as the priority; response may include escalation, remediation, suspension, termination or reporting where legally required.
Governance and effectiveness
The Board owns this policy. Procurement, quality and operations roles will be assigned as the operating model matures. Effectiveness measures will be defined from real onboarding and incident data, such as risk-screen completion, evidence gaps and corrective actions; no unsupported zero-risk or zero-incident claim is made.
The current statutory threshold is described in the UK Government's transparency in supply chains guidance.